Page 4 of 8: studies 31 to 40 of 76, newest first. Back to the MDMA for addiction overview
March 1, 2023 David Nutt, David Castle 4 citations
Abstract There is substantial contemporary interest in psychedelic agents as medicines for maladies of the mind. This follows research in the 1950s and 1960s exploring the use of LSD and other psychedelics to treat a range of psychiatric illnesses as well as addictions. This research was shut down after prohibition of these drugs; however, the last decade has seen a major renewal of interest in...
International review of psychiatry (Abingdon, England) 2023 Fabio Carezzato, Ilana Falcão de Arruda, Caio Petrus Monteiro Figueiredo et al. 4 citations
This comprehensive review delves into the intricate interplay between gender/sex and MDMA use, drawing upon recent evidence. It explores how girls, as a means of coping with negative emotions, often resort to drug use, while boys primarily initiate drug use due to peer pressure or sensation-seeking tendencies. Women, frequently having endured traumatic life events, may turn to MDMA as a form of...
Addiction Science & Clinical Practice September 4, 2022 Lukas Andreas Basedow, Melina Felicitas Wiedmann, Veit Roessner et al. 17 citations
Abstract Background Post-traumatic stress disorder (PTSD) and substance use disorders (SUDs) often co-occur in adolescent patients. Previous research has shown that these patients differ from SUD patients without PTSD in terms of their substance use patterns. In this study, we aimed to test whether substance use in this population is related to an attempt to self-medicate PTSD-related symptoms....
Psychopharmacology March 1, 2022 Madeline M. Pantoni, Jinah L. Kim, Kaitlin R. Van Alstyne et al.
Abstract Rationale ±3,4-Methylenedioxymethamphetamine (MDMA) is a recreational drug that shows substantial promise as a psychotherapeutic agent. Still, there is some concern regarding its behavioral toxicity, and its dose-effect relationship is poorly understood. We previously explored the role of dose in the cognitive effects of MDMA in a systematic review of existing literature and found no...
Journal of Clinical Medicine February 15, 2022 Lourdes Poyatos, A Acuna Torres, Esther Papaseit et al. 26 citations
Introduction and objective: Assessing the abuse potential of new substances with central nervous system activity is essential for preventing possible risks of misuse and addiction. The same methodology is recommended for the evaluation of the abuse potential of recreational drugs. This systematic review aims to assess the pharmacological effects related to the abuse potential and...
Frontiers in Psychiatry January 21, 2022 Melina Wiedmann, Sören Kuitunen-Paul, Lukas A Basedow et al. 5 citations
ObjectivesBoth substance use, on the one hand, and the first signs of psychosis, on the other, commonly begin in adolescence. Adolescents with substance use disorder (SUD) frequently show recreational use of cannabis and 3,4-methylenedioxymethamphetamine (MDMA). When attenuated psychotic symptoms (APS) occur during the course of SUD, they are commonly attributed to the cannabis use, neglecting...
Canadian Journal of Health Technologies June 24, 2021 Yi‐sheng Chao, Jennifer Horton 5 citations
Two systematic reviews, 3 randomized controlled trials, and 2 single-arm safety trials were identified that evaluated several combinations of psychedelic-assisted psychotherapy. Psilocybin was the psychedelic most tested. Other psychedelics identified in the systematic reviews and primary studies were 3,4-methylenedioxymethamphetamine (or MDMA), lysergic acid diethylamide (or LSD), ayahuasca...
European Psychiatry April 1, 2021 Clayton Peixoto, Fabiano Santos, Daianne Cardinalli Rêgo et al. 1 citation
Introduction Recently there has been renewal in interest of psychedelic research. Classic psychedelics such as lysergic acid diethylamide (LSD), psilocybin and mescaline act pharmacologically as agonists at the 5-HT2A receptor. The entactogens like methylenedioxymethamphetamine (MDMA), acts as a serotonin, dopamine and noradrenaline agonist. All of these drugs are potential candidates in the...
Journal of Psychopharmacology February 18, 2021 Ben Sessa, Laurie Higbed, Steve O’Brien et al. 123 citations
Background: 3,4-methylenedioxymethamphetamine (MDMA) therapy has qualities that make it potentially well suited for patients with addictions, but this has never been explored in a research study. We present data from the Bristol Imperial MDMA in Alcoholism (BIMA) study. This is the first MDMA addiction study, an open-label safety and tolerability proof-of-concept study investigating the...
Pharmacology Biochemistry and Behavior January 27, 2021 M.l. Shawn Bates, Keith A Trujillo 57 citations
Adolescence is a period of profound developmental changes, which run the gamut from behavioral and neural to physiological and hormonal. It is also a time at which there is an increased propensity to engage in risk-taking and impulsive behaviors like drug use. This review examines the human and preclinical literature on adolescent drug use and its consequences, with a focus on dissociatives...